Dechra to acquire worldwide rights to the Osurnia from Elanco Animal Health
LONDON: Dechra Pharmaceuticals has agreed terms to acquire the worldwide rights to the Osurnia product portfolio from Elanco Animal Health Incorporated for a total consideration of USD 135 million. The…